Dr. Grey AI

Pramlintide (Symlin)

Peptide

Pramlintide is a synthetic analog of human amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. FDA-approved in 2005, it is used as adjunctive therapy to mealtime insulin in type 1 and type 2 diabetes. Clinical trials showed HbA1c reductions of 0.3-0.62% plus weight loss, with 48% achieving dual improvement in HbA1c and weight (vs 16% placebo).

Quick Answer

What it is

Pramlintide is a synthetic analog of human amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. FDA-approved in 2005, it is used as adjunctive therapy to mealtime insulin in type 1 and type 2 diabetes.

Key findings

  • Grade A: HbA1c Reduction (Type 2 Diabetes)
  • Grade A: Postprandial Glucose (Type 2 Diabetes)
  • Grade A: Body Weight (Type 2 Diabetes)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Pramlintide (Symlin)

Quick Facts: Pramlintide (Symlin)

  • Best Evidence:Grade A
  • Conditions Studied:2
  • Research Outcomes:10
  • Grade A Findings:5
  • Grade B Findings:2
  • Key Effect:Type 2 Diabetes
A5
B2
C2
D1
2 conditions · 10 outcomes

Detailed Outcomes

|
A
HbA1c Reduction
52-week RCT: 0.3-0.62% HbA1c reduction vs placebo. Improvement achieved without increase in insulin dose or severe hypoglycemia.
moderate↓Improves
A
Postprandial Glucose
1-hour PPG reduced by 4.8 mmol/L, 2-hour PPG reduced by 3.4 mmol/L in clinical trials.
large↓Improves
A
Body Weight
Significant weight reduction in all dose groups vs placebo. 48% achieved combined HbA1c + weight reduction (vs 16% placebo).
moderate↓Improves
A
Postprandial Glucagon
Significant suppression of postprandial glucagon secretion, reducing inappropriate hepatic glucose output after meals.
moderate↓Improves
B
Lipid Profile
Reductions in plasma total and LDL cholesterol observed in 4-week trial supporting improved metabolic control.
small↓Improves
A
HbA1c Reduction (Type 1)
FDA-approved for type 1 diabetes. Long-term studies show HbA1c and weight reduction without increased severe hypoglycemia.
moderate↓Improves
B
Blood Glucose Control
52 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↓Improves
C
Liver Protection
4 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
C
Neuroprotection
3 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
D
Oxidative Stress
2 preclinical studies support this finding. Primarily preclinical evidence.
small↓Improves

Research Citations (34)

Pramlintide an Adjunct to Insulin Therapy: Challenges and Recent Progress in Delivery.
(2024)
PMID: 37863489
Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada.
(2024)
PMID: 38906614
Liraglutide versus pramlintide in protecting against cognitive function impairment through affecting PI3K/AKT/GSK-3β/TTBK1 pathway and decreasing Tau hyperphosphorylation in high-fat diet- streptozocin rat model.
(2024)
PMID: 38536493
Treating obesity in type 1 diabetes mellitus - review of efficacy and safety.
(2024)
PMID: 37820077
Pramlintide: An Amylin Analogue Protects Endothelial Cells against Oxidative Stress through Regulating Oxidative Markers and NF-κb Expression.
(2022)
PMID: 35392304
Alleviating carbohydrate counting with a FiASP-plus-pramlintide closed-loop delivery system (artificial pancreas): Feasibility and pilot studies.
(2021)
PMID: 34047449
Neuroprotective Effects of the Amylin Analog, Pramlintide, on Alzheimer's Disease Are Associated with Oxidative Stress Regulation Mechanisms.
(2019)
PMID: 30958347
Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease.
(2018)
PMID: 29480193
Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.
(2015)
PMID: 25590213
The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis.
(2011)
PMID: 21199269